Trial Profile
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concomitant Chemotherapy and Radiotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Clazakizumab (Primary)
- Indications Mucositis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lundbeck Seattle BioPharmaceuticals Inc.
- 29 Oct 2014 New trial record